AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00218543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: At the start of week 7, patients will be maintained at 80 mg/day or increased to the maximal dose of 100 mg/day if less than a 50% reduction of symptoms on the ADHD Rating Scale occurs, and if the patient is tolerating the medication well.
Study NCT02919033 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: The hypertension care of this arm complies with the national guideline and includes designated follow-ups by PCPs once every 1-3 months for stage-1 (≥ 140/90 mm Hg) hypertension patients, once every 1 month for stage-2 (≥ 160/100 mm Hg) and once every 2 weeks for stage-3 (≥ 180/110 mm Hg) patients.
Study NCT02919033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-management
Description: * Usual care~* Patients receive a BP telemedicine system developed by CareLinker Inc. (Shanghai, China) to facilitate BP self-management in addition to all the usual care components. The system consists of: 1) a BP tele-monitor with embedded GSM module that can upload BP readings; 2) a mobile App that allows patients to manually input healthcare data, display history BP measurements and lab test results, receive personalized lifestyle coaching contents and medication reminders, and communicate with PCPs through text-messaging.~* All patients receive proficiency training in using the BP tele-monitor, and mobile App.
Study NCT02919033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCTM intervention
Description: * Usual care~* Self-management~* PCPs and cardiologists use the secure CareLinker website to review patient data including BP measurements, lab test results and medications in use and comorbidities. The auto analytics tools of the website reveal BP average, BP trend, and risk score of each patient. Text alerts of abnormal BP variability will be pushed to PCPs' App when they occur and proactive interventions including phone consultation and medication dosage adjustment will be offered. A case review session will be set once every 1-2 months for PCPs and cardiologists to exam patients' disease progresses. The proprietary web-based analytic module also produces automated individualized medication recommendations to PCPs.~* PCPs and cardiologists receive training of the CareLinker website.
Study NCT01585480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Gain Prevention Intervention
Description: 1. Behavioral Approaches~   1. Distribution of pedometers~  2. Traffic light labeling in worksite cafeteria and vending machines~2. Informational \& Persuasive Messages~   1. Stair use prompts~  2. Posters, pamphlets, table toppers~  3. Website~3. Social Approaches~   a. Identification and training of influential employees (Peer Helpers) to shape healthy norms~4. Environmental Changes~   1. Traffic light labeling~  2. 1/2 portions at 1/2 price~  3. Walking routes~  4. Introduction of healthier foods~  5. Rearrangement of foods in the cafeteria~  6. Adjusting serving spoon size
Study NCT01864291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)
Description: Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
Study NCT03621657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.
Study NCT01473732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Starting dose 1.5 mg bid, target trough level 6-10 ng/ml.
Study NCT04464642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 25 mg subcutaneous is given in group A
Study NCT04464642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: tofacitinib 10 mg given in group B
Study NCT01473732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Target trough level of Tacrolimus 3-5 ng/ml.
Study NCT01473732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid
Description: Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Used in both arms. Used for one year.
Study NCT01095458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone versus Clinic Weight Management Programs
Description: To determine if weight loss is equivalent between individuals that complete weight loss meetings in person versus on the phone.
Study NCT04724070 — intervention group
Intervention type: GENETIC
Intervention: NGS, PDO/PDX establishment
Description: Patients' tumor specimens will be collected for next generation sequencing, PDO/PDX establishment and tissue banking.
Study NCT01473732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic acid
Description: Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Used in both arms. Used for one year.
Study NCT03058692 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Multimeric-001 Vaccine
Description: The M-001 vaccine consists of 3 repetitions of 9 conserved linear epitopes that are prepared as a single recombinant protein. The M-001 vaccine is expected to protect against existing as well as future seasonal and pandemic virus strains.
Study NCT03058692 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is saline injection
Study NCT03058692 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Seasonal Influenza Vaccine
Description: Quadrivalent Inactivated Influenza Vaccine (IIV4) for intramuscular injection is indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.
Study NCT03058692 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Quadrivalent Recombinant Seasonal Influenza Vaccine
Description: Quadrivalent Inactivated Influenza Vaccine (IIV4) for intramuscular injection is indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.
Study NCT02820675 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: structured case analysis
Description: implementation of a structured analysis of cases coded as sepsis, severe sepsis, or septic shock after risk adjustment for low-risk-fatalities, high-risk-survivors, and coding errors for preventable deaths, best practice, quality improvement and improvement in coding precision.
Study NCT02820675 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: strucured screening every patient, every shift
Description: implementation of a strutured screening and rescue algorithm on regular wards, emergency departements, and intermediate and intensive care units by checking every patient in every shifts for clinical signs of deterioration and apllying a rescue algorithm including consiliary help and/or the help of outreach teams
Study NCT00574717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Infants will receive spectacles with 3.00D of under-correction relative to the spherical equivalent in each eye as measured by the cycloplegic retinoscopy performed at baseline. They will also receive the full amount of measured astigmatism in their glasses. Changes in spectacle lens power will be made as needed at follow-up visits to keep the level of under-correction within 0.50D of the target 3.00D. A program of visual engagement is also provided to encourage the normal development and use of accommodation. Treatment will continue for 15 months (until 18 months of age) or until the infant reaches a spherical equivalent refractive error of +3.00D or less hyperopia.
Study NCT00974753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac 0.5%
Description: Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
Study NCT00974753 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline drops
Description: Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
Study NCT02688244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation
Description: Irrigation of the abdominal cavity with at least 300ml of normal saline using the power suction/irrigator
Study NCT02688244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No irrigation
Description: Suction only, using suction device
Study NCT03536585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vulvovaginal treatment
Description: * Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.~* Radiofrequency and pulsed electro-magnetic fields treatment of the labia to maintain an external temperature of approximately 40 C - 45 C for 15 minutes.~* Radiofrequency and pulsed electro-magnetic fields treatment of the mons pubis to maintain an external temperature of approximately 40 C - 47 C for 15 minutes.
Study NCT03536585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baseline
Description: Subject is acting as their own control. The baseline general appearance photograph will act as the comparator.
Study NCT01798966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish
Study NCT03576326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drawing Incentive
Description: The Monetary Reward intervention is a drawing reward, in which participants are eligible for weekly rewards based on toothbrushing performance.
Study NCT01759797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intra venous injection of stem cell
Description: Intra venous injection of mesenchymal stem cell
Study NCT02582645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open window technique
Description: palatally impacted canine will be exposed and left without traction for a maximum of 9 months
Study NCT02582645 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closed window technique
Description: palatally impacted canine will be exposed, an attachment will be bonded, and then the canine will be covered with palatal tissue; traction of the canine will be initiated within 2 weeks following surgery
Study NCT00497445 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: angioplasty / surgery
Description: Percutaneous vascular intervention or surgery for peripheral arterial disease
Study NCT00497445 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioplasty / surgery and exercise therapy
Description: Percutaneous vascular intervention or surgery for peripheral arterial disease followed by supervised exercise therapy
Study NCT02994537 — intervention group
Intervention type: OTHER
Intervention: Different biochemical results or pathogenesis.
Description: Comparing the pathogenesis,clinical characteristics and treatment effects between the acute autoimmune hepatitis group and the chronic autoimmune hepatitis group. The investigators don't use special intervention.
Study NCT03242681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy Assisted Probing procedure
Description: The patency of the system will be tested by irrigation with 1 ml normal saline. A cannula was introduced via the upper or lower canaliculus as far as the lacrimal sac and fluid injected through the system from a 5 ml syringe. Nasal endoscopy and irrigation will be performed simultaneously and free flow of fluid from the lacrimal sac to the nose will confirm anatomical patency of the system
Study NCT03667755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fast track recovery surgery with whey protein infused carbohydrate loading and early oral feeding
Description: participants will be carbohydrate loaded with whey protein infused carbohydrate drink and started on early oral feeding post-operation
Study NCT06371105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10-week water-based aerobic training
Description: The water-based aerobic program was adopted from the protocol previously used by Costa et al. (2018, 2020). This training program was carried out thrice a week over 2 non-consecutive days 48 hours apart for 10 weeks according to ACSM guidelines
Study NCT01751984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: Weeks 1-2, 60 milligrams per day (mg/day); Weeks 3-4, 120 mg/day; Weeks 5-6, 180 mg/day; Weeks 7-8, 240 mg/day
Study NCT01751984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 8 weeks
Study NCT04186234 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: Stereotactic body radiation therapy of 30 to 50 Grays in 5 fractions before liver transplantation
Study NCT03870295 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sympathetic skin response (SSR) measure
Description: Ankle - ground distance measurement, hand and foot cutaneous temperature reading, low intensity electrical stimulations on hand and on foot to determine SSR at these two points and DN4 questionnaire to assess the possible presence of neuropathic pain
Study NCT03870295 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sympathetic skin response (SSR) measure
Description: Ankle - ground distance measurement, hand and foot cutaneous temperature reading, low intensity electrical stimulations on hand and on foot to determine SSR at these two points and DN4 questionnaire to assess the possible presence of neuropathic pain
Study NCT06054100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Tablets
Description: Colchicine oral tablets loading dose of 1mg every 12 hrs for 1 day, followed by 0.5 mg BID for 3 months
Study NCT04145882 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: additional osteotomies
Description: varisation osteotomy, supination osteotomy or both
Study NCT00857922 — intervention group
Intervention type: OTHER
Intervention: tissue and data repository
Description: Tissue and data will be maintained in a repository for study from consenting subjects.
Study NCT04145882 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: additional osteotomies
Description: varisation osteotomy, supination osteotomy or both
Study NCT02433886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gamma Ventral Capsulotomy
Study NCT02575755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin plus piperaquine phosphate
Study NCT02575755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Study NCT01429493 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Radiotherapy
Description: Conventional radiotherapy will be used (8 Gy/ 1 fraction).
Study NCT01429493 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Biological image-guided radiotherapy with conventional dose.
Description: Biological image-guided radiotherapy on the positron emitting tomography (PET) positive lesion with conventional dose (8Gy/ 1 fraction) will be used.
Study NCT01429493 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Biological image-guided SBRT with dose-escalation.
Description: Biological image-guided stereotactic body radiotherapy (SBRT) with dose-escalation on the PET positive lesion will be used.
Study NCT02495129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736 lower dose
Description: Patients will receive a total number of 3 monthly subcutaneous injections with the lower dose of VAY736
Study NCT02495129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736 higher dose
Description: Patients will receive a total number of 3 monthly subcutaneous injections with the higher dose of VAY736
Study NCT04050059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA cream
Description: EMLA cream (5g tube Aspen pharma trading limited) will be applied topically in dose of 2.5 grams (half tube of cream) and area will be covered with tegaderm dressing. Application of EMLA will at least stay for 30 minutes before spinal needle insertion
Study NCT04050059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine
Description: In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited), skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60 mg) before spinal needle insertion
Study NCT01103765 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: post dilatation after stent deployment
Description: Post-dilatation with a noncompliant balloon larger 0.25mm than stent balloon.
Study NCT01103765 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: stent deployment without post-dilatation
Description: stent deployment without systematic post dilatation
Study NCT02246595 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CaCP29
Study NCT02246595 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03200119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily health-related lifestyle modification prescription
Description: Daily health-related lifestyle modification prescription
Study NCT00257699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole placebo
Study NCT00257699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ciprofloxacin placebo
Study NCT00257699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Description: 500 mg bid po
Study NCT00257699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole
Description: 250 mg bid po / 250 mg tid po / 500 mg bid po depending on body weight
Study NCT03242681 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy Assisted Probing procedure
Description: The patency of the system will be tested by irrigation with 1 ml normal saline. A cannula was introduced via the upper or lower canaliculus as far as the lacrimal sac and fluid injected through the system from a 5 ml syringe. Nasal endoscopy and irrigation will be performed simultaneously and free flow of fluid from the lacrimal sac to the nose will confirm anatomical patency of the system
Study NCT04482296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI with Zinc Sulfate
Description: Zinc sulfate (30 mg) once daily for 8 weeks SSRI
Study NCT03461107 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT00918099 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Avaulta mesh
Description: Insertion of a mesh vs conventional repair
Study NCT00918099 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior repair
Description: Conventional repair
Study NCT01708512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT03946748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3918
Description: Single intravenous (IV) dose, then a subcutaneous (SC) dose once weekly (QW).
Study NCT02722954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demcizumab
Description: Drug: Demcizumab at starting dose of 2.5mg/kg administered intravenously (IV).
Study NCT01618799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: 2 x 25 mg tablet once a day
Study NCT02722954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Drug: Pembrolizumab administered 2mg/kg IV every 3 weeks
Study NCT04184830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive brain stimulation
Study NCT04184830 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: non-invasive brain stimulation
Study NCT02619474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whiteboard
Description: 1. On morning rounds, the child's management will be discussed with the family and the day's plan for treatment and investigations will be written on the whiteboard.~2. The second step will be to review and update the whiteboard at the end of the day. Anything that has been left out or uncompleted will be highlighted and brought up on the following morning's rounds. Next, the nurse will ask the family to write down any questions.~3. Lastly, on the afternoon before a child's discharge, the nurse will take particular care to make sure the parents write down all of their concerns prior to going home. These specific questions concerning discharge planning will be addressed in detail at rounds the following morning.
Study NCT03499184 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: P Flor locally delivered
Description: Locally delivered Lactobacillus reuteri 1.2 CFU per gram
Study NCT03499184 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: P Flor systemically administered
Description: Systemically administered Lactobacillus reuteri 1.2 CFU per gram
Study NCT03499184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxil 500 mg Oral Capsule
Description: Systemically administered Amoxil 500 mg thrice daily
Study NCT03499184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flagyl 400 mg Tablet
Description: Systemically administered Metronidazole 400 mg twice daily
Study NCT02720341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARMin
Description: single sessions of about one hour each
Study NCT03746327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sivextro 200 milligrams Oral Tablet
Description: 200 mg milligram per day during 4 weeks